Correlation between Programmed Death Ligand-1 (PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype

BACKGROUND: Targeted therapy in adenocarcinoma is recommended. The use of immune check point inhibitors for the treatment of Non-small cell lung carcinoma (NSCLC) is used as both first-line and the second-line treatment strategy. The current study was undertaken to assess the frequency of programmed...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandey, Rahul Kumar, Shukla, Saumya, Husain, Nuzhat, Islam, Mohammad Hayatul, Hadi, Rahat, Tripathi, Surya Kant, Singhal, Ashish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258661/
https://www.ncbi.nlm.nih.gov/pubmed/35092381
http://dx.doi.org/10.31557/APJCP.2022.23.1.131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258661/
https://www.ncbi.nlm.nih.gov/pubmed/35092381
http://dx.doi.org/10.31557/APJCP.2022.23.1.131

Ejemplares similares